Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2007-08-14
2007-08-14
Yaen, Christopher H. (Department: 1643)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S143100, C424S144100, C424S145100, C514S002600, C514S008100, C530S395000, C530S387100
Reexamination Certificate
active
09299139
ABSTRACT:
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
REFERENCES:
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 2002/0197254 (2002-12-01), Browning et al.
patent: WO-92/00329 (1992-01-01), None
patent: WO 94/046679 (1994-03-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO 97/03678 (1997-02-01), None
patent: WO-97/03687 (1997-02-01), None
Ettinger et al PNAS USA Nov.1996 93:13102-13107
Alimzhanov et al., 1997, Proc. Natl. Acad. Sci., 94:9302-9307, “Abnormal development of secondary lymphoid tissues in lymphotoxin Beta-deficient mice”.
Androlewicz et al., 1992, J. of Biol. Chem., 267:2542-2547, “Lymphotoxin Is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma”.
Arulanandam et al., 1993, J. Exp. Med., 177:1439-1450, “A Soluble Multimeric Recombinant CD2 Protein Identified CD48 As A Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands During The Evolution of Humans and Mice”.
Banks et al., 1995, J. of Immunol. 155:1687-1693, “Lymphotoxin-Alpha-Deficient Mice”.
Barnetson et al., 1993, Mosby-Year Book Europe Ltd., 22.1-22.12, “Hypersensitivity-Type I V”.
Briskin et al., 1993, Nature, 363:461-464, “MAdCAM-1 Has Homology TO Immunoglobulin And Mucin-Like Adhesion Receptors And TO IgA1”.
Browning J., Androlewicz, M. et al., 1991, J. of Immunol. 147:1230-1237, “Lymphotoxin And An Associated 33-kDa Glycoprotein Are Expredded On the Surface Of An Activated Human T Cell Hybridoma”.
Browning J., Douglas, I., et al., 1995, American Association of Immunol., 33-46, “Characterization of Surface Lymphotoxin Forms”.
Browning, J., Ngam-ek, A., et al., 1993, 73:847-856, “Lymphotoxin-Beta, A Novel Member of the TNF Family That Forms a Heteromeric Complex With Lymphotoxin On the Cell Surface”.
Cavert, W. et al., 1997, 276:960-964, “Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection”.
Chen, C. et al., 1995, Trends in Biol. Sci., 20:465-470, “AU-rich Elements: Characterization and Importance In mRNA Degradation”.
Crowe, P. et al., 1994, Science, 264:707-710, “A Lymphotoxin-Beta-Specific Receptor”.
DeTongi, P. et al., 1994, Science, 264:703-706, “Abnormal Development Of PEripheral Lymphoid Organs in Mice Deficient in Lymphotoxin”.
Dijkstra et al., 1985, Immunology, 55:23-30, “Marginal Zone Macrophages Identified BY A Monocolnal Antibody: Characterization of Immuno-and Enzyme-Histochemical Properties and Functional Capacities”.
Duzgunesa et al., Q514:77, “Liposome Targeting TO HIV-Infected Cells Via Recombinant Soluble CD4 And CD4-IgG (Immunoadhesin)”.
Endres et al., 1999, J. of Med., 189:159-167, “Mature Follicular Dendritic Cell Networks Depend on Expression Of Lymphotoxin Beta Receptor By Radioresistant Stromal Cells And Of Lymphotoxin Beta And Tumor Necrosis Factor By B Cells”.
Eppstein et al., 1985, Proc. Natl. Acad. Sci., 82:3688-3692, “Biological Activity Of Liposome-Encapsulated Murine Interferon Gamma Is Mediated by A Cell Membrane Receptor”.
Erickson et al., 1994, Nature, 372:560-563, “Decreased Sensitivity To Tumour-Necrosis Factor But Normal T-cell Development in TNF Receptor-2-Deficient Mice”.
Ettinger et al., 1996, Proc. Natl. Acad., 93:13102-13107, “Disrupted Splenic Architecture, But Normal Lymph Node Development In Mice Expressing A Soluble Lymphotoxin-Beta Receptor-IgG1 Fusion Protein”.
Fitch et al., 1993, Annu. Rev. Immunol., 11:29-48, “Differential Regulation Of Murine Lymphocyte Subsets”.
Force et al., 1995, American Association of Immunol., 5280-5288, “Mouse Lymphotoxin-Beta Receptor”.
Foy et al., 1994, J. Exp. Med., 180:157-163, “gp39-CD40 Interactions Are Essential For Germinal Center Formation and the Development of B Cell Memory”.
Fu, Chaplin, et al., 1999, Annu. Rev. Immunol., 17:399-433, “Development and Maturation of Secondary Lymphoid Tissues”.
Fu, Huang, et al., 1998, J. Exp. Med., 187:10091018, “B Lymphocytes Induce the Formation of Follicular Dendritic Cell Clusters in a Lymphotoxin-Alpha-Dependent Fashion”.
Fu, Molina, et al., 1997, J. Exp. Med., 185:2111-2120, Lymphotoxin-Alpha (LTa) Supports Development of Splenic Follicular Structure That Is Required for IgG Responses.
Futterer et al., 1998, Immunity, 9:59-70, “The Lymphotoxin Beta Receptor Controls Organogenesis and Affinity Maturation in Peripheral Lymphoid Tissues”.
Gonzalez et al., 1998, J. Exp. Med., 187:997-1007, “The Sequential Role of Lymphotoxin and B Cells in the Development of Splenic Follicles”.
Han et al., 1995, American Association iof Immunol., 556-567, “Cellular Interaction in Germinal Centers”.
Heath et al., 1995, Nature, 377:740-744, “Follicular Dendritic Cells And Human Immunodeficiency Virus Infectivity”.
Hwang et al., 1980, Proc. Natl. Acad., 77:4030-4034, “Hepatic Uptake And Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study”.
Kraal, Geroge, 1992, Academic Press, 132:31-74, “Cells In the Marginal Zone of the Spleen”.
Kraal and Janse, 1986, Immunology, 58:665-669, “Marginal Metallophic Cells Of the Mouse Spleen Identified By a Monoclonal Antibody”.
Kraal, Rodrigues, et al., 1989, Immunology, 68:227-232, “Lymphocyte Migration in the Spleen: the Effect of Macrophage Elimination”.
Kraal, Schornagel, et al., 1995, American Journal of Pathology, 147:763-771, “Expression of the Mucosal Vascular Addressin, MAdCAM-1, on Sinus-Lining Cells in the Spleen”.
Kratz et sl., 1996, J. Exp. Med., 183:1461-1472, “Chronic Imflammation Caused by Lymphotoxin Is Lymphoid Neogenesis”.
Laman et al., 1996, Critical Reviews in Immunol., 16:59-108, “Functions of CD40 and Its Ligang, gp39 (CD40L)”.
Lane et al., 1992, Eur. J. Immunol., 22:2573-2578, “Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell -dependent activation of B lymphocytes”.
Langer, 1982, Chemtech, Feb., 98-105, “Controlled release of macromolecules”.
Langer, Brem, et al., 1981, J. of Biomed. Materials, 15:267-277, “Biocompatibility of polymeric delivery systems for macromolecules”.
Le Hir, et al., 1996, J. Exp. Med., 183:2367-2372, “Differentation of Follicular Dendric Cells and Full Antibody Responses Reuqire Tumor Necrosis Factor Receptor-1 Signaling”.
Mackay et al., 1997, Eur. J. Immunol., 27:2033-2042, “Lymphotoxin but not tumor necrosis factor functions to maintain splenic arcitecture and humoral responsiveness in adult mice”.
MacLennan et al., 1993, Blackwell Scientific Publications, 5:13-30, “The Structure and Function of Secondary Lymphoid Tissue”.
Maeda et al., 1992, J. of Immunol., 148:2340-2347, “Murine Follicular Dendritic Cells and Low Affinity Fc Receptors For IgE (FceRII)1”.
Male et al., 1993, Mosby-Year Book Europe, 3rd ed., 1:1.1-1.2, “Introduction to the Immune System”.
Matsumoto, Chaplin, et al., 1997, Immunol. Reviews, 156:137-144, :Lymphotoxin-alpha-deficient and TNF receptor-1-deficient mice define developmental and functional characteristics of germinal centers.
Matsumoto, Huang, et al., 1997, J. Exp. Med., 186:1997-2004, “Distinct Roles of Lymphotoxin alpha and the Type 1 Tumor Necrosis Factor (TNF) Receptor i
Browning Jeffrey L.
Hochman Paula S.
Mackay Fabienne
Rennert Paul D.
Biogen Inc.
Howley Cristin E.
Lahive & Cockfield LLP
Mandragouras Amy E.
Yaen Christopher H.
LandOfFree
Use of lymphotoxin-β receptor blocking agents for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of lymphotoxin-β receptor blocking agents for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of lymphotoxin-β receptor blocking agents for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3887715